Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?
- PMID: 35909260
- DOI: 10.1093/eurheartj/ehac387
Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?
Conflict of interest statement
Conflict of interest: J.B. received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, and Corvia, not related to this article; and research support for the department from Zoll, CVRx, and Abiomed, not related to this article. K.M.O. has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, Pfizer, and United Therapeutics.
Comment on
-
Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.Eur Heart J. 2022 Sep 21;43(36):3402-3413. doi: 10.1093/eurheartj/ehac389. Eur Heart J. 2022. PMID: 35909264 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical